Peater Piper
Member
- Joined
- Mar 18, 2016
- Messages
- 814
This regards niacin. I don't know if would also apply to niacinamide, hence posting it here to get opinions.
http://www.jlr.org/content/early/2014/10/15/jlr.M051938.full.pdf
The gene expression profile of gonadal white adipose tissue (gWAT) from niacin treated mice showed an up-regulation of the “biosynthesis of poly unsaturated fatty acid (PUFA)” pathway, which was corroborated by qPCR and analysis of the FA ratios in gWAT. Also, adipocytes from niacin treated mice secreted more of the PUFA docosahexaenoic acid (DHA) ex vivo. This resulted in an increased DHA/arachidonic acid (AA) ratio in the adipocyte FA secretion profile and in plasma of niacin treated mice. Interestingly, the DHA metabolite 19,20-dihydroxy docosapentaenoic acid (19,20-diHDPA) was increased in plasma of niacin treated mice. Both an increased DHA/AA ratio and increased 19,20-diHDPA are indicative for an anti-inflammatory profile and may indirectly contribute to the atheroprotective lipid and lipoprotein profile associated with prolonged niacin treatment.
The current study demonstrates for the first time that prolonged niacin treatment results in an upregulation of the n-3 PUFA synthesis pathway in adipose tissue. Gene expression analysis of gWAT showed that our hyperlipidemic mouse model responded to niacin by up-regulating genes involved in the unsaturated FA biosynthesis. Fatty acid composition analysis corroborated the increased PUFA synthesis. A higher degree of n-3 PUFA secretion from prolonged niacin treated adipocytes was seen, which was also reflected in increased n-3 PUFA plasma levels. Markedly, the plasma levels of n-3 PUFA derived oxylipins produced by cytochrome P450 and hydrolyzed by soluble epoxy hydrolases were increased. Oxylipins produced by cytochrome P450 from n-3 PUFAs and the n-3 PUFAs themselves suggest a beneficial vascular health profile, which might contribute to the prolonged niacin-induced atheroprotective effect.
http://www.jlr.org/content/early/2014/10/15/jlr.M051938.full.pdf